SCHEMBL7679108

SCHEMBL7679108

CC(=O)Oc1cccc([C]=O)c1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.59
CYP3A4 P08684 1/20 0.59
ACHE P22303 2/20 0.54
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KDM4E B2RXH2 1/20 0.42
MAPT P10636 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
ELANE P08246 1/20 0.42
GAA P10253 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3828627 0.84 LMNA (0.58) LMNACYP3A4ACHEKMT2AMEN1
SCHEMBL10547627 0.84 CYP3A4 (0.58) LMNACYP3A4ACHEKMT2AMEN1
SCHEMBL16953007 0.84 LMNA (0.58) LMNACYP3A4ACHEKMT2AMEN1
SCHEMBL30676498 0.84 CYP3A4 (0.58) LMNACYP3A4ACHEKMT2AMEN1
SCHEMBL15611000 0.82 CYP3A4 (0.56) LMNACYP3A4ACHEKMT2AMEN1
SCHEMBL249305 0.82 LMNA (0.76) LMNACYP3A4ACHEKMT2AMEN1
SCHEMBL17028900 0.82 LMNA (0.76) LMNACYP3A4ACHEKMT2AMEN1
SCHEMBL7677883 0.81 ACHE (0.58) LMNAACHEKMT2AMEN1ALDH1A1
SCHEMBL7282741 0.80 LMNA (0.47) LMNACYP3A4ACHEKMT2AMEN1
SCHEMBL6829778 0.80 LMNA (0.43) LMNACYP3A4ACHEKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230391828-A1 REGULATORS OF CELL DIVISION TECHNISCHE UNIVERSITAT DRESDEN (DE) 2023-12-07 US claimed
EP-4225780-A2 REGULATORS OF CELL DIVISION Technische Universität Dresden (DE) 2023-08-16 EP claimed
WO-2022074072-A2 REGULATORS OF CELL DIVISION Technische Universität Dresden (DE) 2022-04-14 WO claimed
CN-110305142-B Stereoselective synthesis method of 6 beta-hydroxymorphine derivative 宜昌人福药业有限责任公司 2021-11-16 CN claimed
US-6380197-B1 FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES AVENTIS PHARMA S. A. (FR) 2002-04-30 US claimed
EP-1001943-A1 POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM Aventis Pharma S.A. (FR) 2000-05-24 EP claimed
WO-1999003843-A1 POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM RHONE-POULENC RORER S.A. (FR) 1999-01-28 WO claimed
CN-118139839-A Process for producing fluorinated polyether 株式会社力森诺科 2024-06-04 CN disclosed
CN-118055920-A Process for producing fluorinated polyether 株式会社力森诺科 2024-05-17 CN disclosed
US-20230391828-A1 REGULATORS OF CELL DIVISION TECHNISCHE UNIVERSITAT DRESDEN (DE) 2023-12-07 US disclosed
EP-4225780-A2 REGULATORS OF CELL DIVISION Technische Universität Dresden (DE) 2023-08-16 EP disclosed
WO-2022074072-A2 REGULATORS OF CELL DIVISION Technische Universität Dresden (DE) 2022-04-14 WO disclosed
CN-110305142-B Stereoselective synthesis method of 6 beta-hydroxymorphine derivative 宜昌人福药业有限责任公司 2021-11-16 CN disclosed
US-4566901-A PLANT SAFENING AGENTS CIBA-GEIGY CORPORATION (US) 1986-01-28 US disclosed
EP-0094348-B1 OXIME ETHERS, PROCESS FOR THEIR PREPARATION, AGENTS CONTAINING THE OXIME ETHERS AND THEIR USE CIBA-GEIGY AG (CH) 1985-07-24 EP disclosed
US-4518596-A Antithrombotic use of 2-(perhydro-1,4-diazino)-pyrimido (5,4,D)-pyrimidines DR. KARL THOMAE GMBH (DE) 1985-05-21 US disclosed
US-4438277-A Hydronaphthalene derivatives SANKYO COMPANY, LIMITED (JP) 1984-03-20 US disclosed
EP-0094348-A1 Oxime ethers, process for their preparation, agents containing the oxime ethers and their use CIBA-GEIGY AG (CH) 1983-11-16 EP disclosed
US-4415572-A CARDIOTONIC AND INOTROPIC AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1983-11-15 US disclosed
US-4361515-A Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use SANKYO COMPANY, LIMITED (JP) 1982-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391828-A1 REGULATORS OF CELL DIVISION PCNA, BOD1L1, MKI67 LMNA 2194/4885CYP3A4 4883/4885ACHE 4884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.